CEA-MUC-1-TRICOM vaccine CV301

{
  "id": "MLC-T-ONC-012482",
  "term": "CEA-MUC-1-TRICOM vaccine CV301",
  "field": "Oncology and biomedicine",
  "definition": "A cancer prime/boost vaccine-based immunotherapeutic consisting of a prime, which is comprised of a proprietary version of the recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN) and a recombinant fowlpox viral vector, used for the boosts, encoding both the two tumor-associated antigens (TAA), carcinoembryonic antigen (CEA) and mucin-1 (MUC-1), and TRICOM, which is comprised of three immune-enhancing co-stimulatory molecules, B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. The administration of the vaccinia priming dose is followed by multiple boosting doses of the fowlpox vector. CEA-MUC-1-TRICOM vaccine CV301 may enhance presentation of CEA and MUC-1 to antigen-presenting cells (APCs) and may activate a cytotoxic T-lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells. In addition, CV301 upregulates the expression of PD-L1 due to CTL-mediated tumor attack; additionally, when combined with a PD-1 immune checkpoint inhibitor, the antitumor effect may be increased. CEA and MUC-1 are overexpressed in certain cancers.",
  "synonyms": [
    "MVA-BN/Fowlpox-CEA-MUC-1-TRICOM vaccine CV301",
    "PANVAC"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/cea-muc-1-tricom-vaccine-cv301/"
}